858.450.2800info@Sudoscan.com
SUDOSCAN® User LOGIN
SUDOSCAN® utility in assessing sudomotor dysfunction in COVID-19 patie Skip to content
  • About SUDOSCAN®
  • Our Company
  • Research, Media & Events
  • Contact
  • Store
  • Log in
  • YouTube
Cart


Subtotal
$0.00
Shipping, taxes, and discount codes calculated at checkout.
Your cart is currently empty.
SUDOSCAN Logo Powered by Withings SUDOSCAN Logo Powered by Withings Sudoscan Logo white SUDOSCAN Logo Powered by Withings
  • About SUDOSCAN®
  • Our Company
  • Research, Media & Events
  • Contact
  • Store
Log in Cart
Create Account
Schedule an online DEMO

Access Denied
IMPORTANT! If you’re a store owner, please make sure you have Customer accounts enabled in your Store Admin, as you have customer based locks set up with EasyLockdown app. Enable Customer Accounts
Home / Research, Media & Events / SUDOSCAN® utility in assessing sudomotor dysfunction in COVID-19 patients.
Infectious disease · News · Feb 18, 2023

SUDOSCAN® utility in assessing sudomotor dysfunction in COVID-19 patients.

SUDOSCAN® utility in assessing sudomotor dysfunction

Sudomotor Dysfunction in COVID-19 Patients after Recovery


Anand Hinduja, Abdul Moutairou, Jean-Henri Calvet
Article title: Sudomotor dysfunction in patients recovered from COVID-19.
Neurophysiologie Clinique/Clinical Neurophysiology, Feb 2021.

Dysautonomia has been reported in COVID-19 infection. Very recently an observational study, performed by Hinduja et al, from Aarti Clinic, Kharghar, Navi Mumbai, India, involved 50 patients who had recovered from COVID-19 and were seen within 3 months post-infection in an outpatient clinic for fatigue or various neurological symptoms.

The NHS (National Health Service) questionnaire for neurological symptoms was completed and electrochemical skin conductance was measured using SUDOSCAN.

Presence of sweat dysfunction (decrease in FESC – Feet Electrochemical Skin Conductance) was observed in 26% of patients, while 6% had severe sweat dysfunction.

These patients with decrease in FESC more frequently reported at least one motor, sensory or autonomic symptom (p = 0.04). See Table 1.

Sudomotor dysfunction in patients recovered from COVID-19
Table 1: Details of symptoms (sensory, motor and autonomic) reported by the patients
in the whole population and according to the presence (FESC <60 µS) or absence
of sudomotor dysfunction (FESC ≥60 µS).

This preliminary observational study reveals that more than 25 % of patients who recovered from COVID-19 and seen in an outpatient clinic, had sweat dysfunction generally reflecting dysautonomia, which could have severe consequences and must be monitored during follow-up.

These findings must be confirmed in a larger population with additional testing but underline the necessity of enhancing screening of dysautonomia in this population of patients recovered from COVID-19.

In this way it could be helpful to test the patients recovered from COVID-19 using SUDOSCAN a very simple and rapid test.

Share Share on Facebook Tweet Tweet on Twitter Pin it Pin on Pinterest

Back to Research, Media & Events
Invalid password
Enter
Sudoscan Logo

SUDOSCAN® is a privately-owned French medical device company.

Created in June 2005, SUDOSCAN is located in San Diego, CA, USA; the company's corporate headquarters are in Paris, France. We service all of the North and South America, The Middle East, Europe and Asia.

  • YouTube

Sudoscan

  • About SUDOSCAN®
  • Our Company
  • Research, Media & Events
  • Contact
  • Store

Shop SUDOSCAN

  • Login
  • Create an account

Resources

  • For Patients
  • For Physicians
  • SUDOSCAN® Articles
  • SUDOSCAN® Videos
  • SUDOSCAN® Image Gallery
  • Reimbursement Regulatory

CONTACT INFO:

US TERRITORIES:
SUDOSCAN Inc.
8525 Gibbs Dr. Suite 304
San Diego, CA 92123

Phone: +1 858 450 2800

INTERNATIONAL:
Impeto Medical
2 Rue Maurice Hartmann,
92130 Issy-les-Moulineaux,
France

Phone: +33 (0)7 87 20 32 03
Website: www.impeto-medical.com/

Promotional Communication. The medical devices SUDOSCAN® is cleared by the US Food and Drug Administration (FDA). The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 05/10/2023

Language

  • English
  • Français

Currency

  • Canada (CAD $)
  • United States (USD $)
  • American Express
  • Apple Pay
  • Diners Club
  • Discover
  • Google Pay
  • Mastercard
  • Shop Pay
  • Visa
© 2023 SUDOSCAN USA | Autonomic & Sudomotor Testing Device Web Development
SUDOSCAN® utility in assessing sudomotor dysfunction in COVID-19 patie